STOCK TITAN

Liminatus Pharma SEC Filings

LIMN NASDAQ

Welcome to our dedicated page for Liminatus Pharma SEC filings (Ticker: LIMN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.

Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Liminatus Pharma's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.

Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Liminatus Pharma's regulatory disclosures and financial reporting.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider

FAQ

What is the current stock price of Liminatus Pharma (LIMN)?

The current stock price of Liminatus Pharma (LIMN) is $6.47 as of July 23, 2025.

What is the market cap of Liminatus Pharma (LIMN)?

The market cap of Liminatus Pharma (LIMN) is approximately 150.4M.
Liminatus Pharma

NASDAQ:LIMN

LIMN Rankings

LIMN Stock Data

150.36M
4.51M
Biological Products, (no Disgnostic Substances)
LA PALMA